

Zacks Small-Cap Research

Sponsored – Impartial - Comprehensive

Michael Kim
312-265-9371
mkim@zacks.com

scr.zacks.com

101 N. Wacker Drive, Chicago, IL 60606

Vireo Growth Inc. (VREOF-OTC)

VREOF: 4Q25 Earnings Preview – Busy Quarter on the M&A Front; Meaningful Upward Revaluation on Deck, as Related Accretion Materializes

While we will wait until 4Q25 earnings to officially update our earnings model and \$1.50 DCF-derived price target, we look for a material upward revaluation for the stock, as deal-related accretion increasingly comes into focus. Furthermore, a more favorable regulatory backdrop (particularly as it relates to federal rescheduling or incremental state legalizations) potentially drives potent business, economic, valuation, and/or uplisting benefits over time.

Current Price (3/9/26) **\$0.42**
Valuation **\$1.50**

OUTLOOK

Key 4Q25 takeaways include: 1) management has remained aggressive on the M&A front, with recent agreements/MOUs to acquire Eaze, PharmaCann, Schwazze, and Hawthorne; 2) on a pro forma basis, Vireo Growth will operate 166 dispensaries across 10 states, with approximately 800,000 square feet of cultivation and production facilities; 3) while we suspect senior officials will provide some color on deal-related accretion on the company's fourth quarter 2025 earnings conference call, our back-of-the-envelope math suggests a material step up in earnings power following the closings; 4) the rescheduling of marijuana from Schedule I to Schedule III potentially paves the way for several key benefits for cannabis-related businesses including the deduction of business expenses on federal tax returns, improved access to banking/financial services, and less onerous tax burdens; and 5) as uncertainty around rescheduling probabilities, implications, and timelines fade, we look for cannabis stocks to benefit from powerful upward revaluations.

SUMMARY DATA

52-Week High **\$0.80**
52-Week Low **\$0.31**
One-Year Return (%) **19.94**
Beta **N/A**
Average Daily Volume (sh) **206,922**

Shares Outstanding (mil) **1,062**
Market Capitalization (\$mil) **\$446**
Short Interest Ratio (days) **N/A**
Institutional Ownership (%) **11**
Insider Ownership (%) **27**

Annual Cash Dividend **\$0.00**
Dividend Yield (%) **0.00**

5-Yr. Historical Growth Rates
Sales (%) **N/A**
Earnings Per Share (%) **N/A**
Dividend (%) **N/A**

P/E using TTM EPS **N/A**
P/E using 2025 Estimate **N/A**
P/E using 2026 Estimate **14.0**

Risk Level **Above Average**
Type of Stock **Small-Growth**
Industry **Medical - Products**

ZACKS ESTIMATES

Revenues

(in thousands of \$)

	Q1	Q2	Q3	Q4	Year
	(Mar)	(Jun)	(Sep)	(Dec)	(Dec)
2023	19,088 A	20,197 A	24,675 A	24,173 A	88,133 A
2024	24,087 A	25,108 A	25,165 A	25,023 A	99,384 A
2025	24,541 A	48,063 A	91,655 A	94,205 E	258,464 E
2026					440,794 E

Earnings/Share

	Q1	Q2	Q3	Q4	Year
	(Mar)	(Jun)	(Sep)	(Dec)	(Dec)
2023	(\$0.07) A	(\$0.06) A	(\$0.04) A	(\$0.03) A	(\$0.19) A
2024	(\$0.05) A	(\$0.00) A	(\$0.02) A	(\$0.07) A	(\$0.16) A
2025	(\$0.02) A	(\$0.03) A	(\$0.04) A	\$0.01 E	(\$0.06) E
2026					\$0.03 E

Quarterly revenues/EPS may not equal annual revenues/EPS due to rounding.

CONTINUING TO EXPAND THE FOOTPRINT

Following the transformational acquisitions of Wholesome, Proper Brands, and Deep Roots Harvest in the first half of 2025, management has remained aggressive on the M&A front. While we walk through each transaction in detail next, management remains focused on building a diversified network of local operators across financially attractive and complementary markets at a high level. On a pro forma basis, Vireo Growth will operate 166 dispensaries across 10 states (CA, CO, FL, MD, MN, MO, NM, NV, NY, and UT), with approximately 800,000 square feet of cultivation and production facilities, as market shares continue to roll up to scale-enabled Multi-State Operators (MSOs). While independent management teams retain control of day-to-day operations, affiliated companies can leverage shared corporate services to facilitate operating efficiencies and enhance growth. From a financing standpoint, Vireo's strong balance sheet remains a key competitive advantage relative to most other U.S.-based cannabis operators that typically struggle to source capital to fund growth due to regulatory restrictions. Indeed, the company maintains ample liquidity to continue to capitalize on accelerating consolidation trends across the industry, with \$117.5 million of cash on the balance sheet as of 9/30/25, as well as long-dated debt maturities and sizeable credit facilities.

Eaze Inc.

In late December 2025, Vireo announced the company entered into a merger agreement with Eaze Inc., a Multi-State Operator with 65 retail dispensaries across California (12), Colorado (14), and Florida (39). The acquisition further diversifies the company's geographic footprint by adding scale-enabled operations in two of the largest markets in the U.S. – California and Florida. Indeed, Eaze manages California's largest legal cannabis marketplace providing access via on-demand delivery, with 12+ million cannabis deliveries since inception, while maintaining outsized cultivation capacity in Florida. Management seems open to further acquisitions in Florida, with Eaze acting as the company's initial beachhead.

In addition to the base consideration of \$47 million (adjusted for cash, indebtedness, transaction expenses, working capital, and tax items) financed by the issuance of 83.9 million subordinate voting shares of VREOF (subject to staggered lock-up periods commencing in March 2027 through March 2028) at \$0.56 per share, former Eaze stockholders may be entitled to earnout payments (in the form of incremental subordinate voting shares of VREOF priced at the higher of \$1.05 or the 20-day Volume-Weighted Average Price as of 12/31/26) based on 3.84x Eaze's Adjusted EBITDA for 2026 less the base consideration. The transaction is expected to close in the first half of 2026.

PharmaCann

In mid-December 2025, Vireo announced the company entered into an Asset Purchase agreement with PharmaCann Inc. involving the sale of 17 retail cannabis dispensaries in Colorado in exchange for a share consideration of \$49 million (adjusted for changes in inventories/trade payables) financed by the issuance of ~116.7 million subordinate voting shares of VREOF (based on the stock's current price), as well as the assumption of certain liabilities. Furthermore, Vireo and PharmaCann entered into a Management Services Agreement, pursuant to which the company will provide certain management services related to the dispensaries until the closing of the transaction (expected in the first half of 2026). Stepping back, the PharmaCann transaction further expands Vireo's retail presence in Colorado to 55 dispensaries on a pro forma basis.

Schwazze

In October 2025, Vireo Growth announced the closing of the acquisition of ~\$91 million of 13% senior secured convertible notes due 12/7/26 issued by Medicine Man Technologies/Schwazze (OTC: SHWZ) in exchange for 114.8 million subordinate voting shares of VREOF at \$0.54 (~\$62 million in aggregate). In conjunction with the transaction, the companies entered into a Restructuring Support Agreement (RSA) that contemplates the sale of select Schwazze assets to a NewCo (majority-owned by Vireo), as well as the liquidation/wind down of Schwazze's remaining operations. Schwazze is currently in default on the company's payment obligations related to the convertible notes. Vireo has secured financing commitments for up to \$62 million for refinancing/working capital needs. Subsequently, Vireo acquired an additional \$2.6 million of the convertible notes in mid-December 2025 bringing the company's ownership stake to 89% of SHWZ's total outstanding senior secured convertible notes.

At a high level, Schwazze is a vertically-integrated Multi-State Operator based in Denver, Colorado, with 46 retail dispensaries and two manufacturing facilities across Colorado and New Mexico. Focusing on Colorado, Schwazze remains the largest cannabis operator in the state, though market shares remain fragmented. That said, the state

seems primed for ongoing consolidation following a more challenging industry backdrop, with VREOF seemingly well positioned to continue to roll up market share, thereby further enhancing the company's scale and buying power in Colorado.

Hawthorne

In January 2026, the company announced a nonbinding Memorandum of Understanding (MOU) with The Scotts Miracle-Gro Company (SMG) to acquire The Hawthorne Gardening Company LLC, a provider of indoor/hydroponic gardening products. The proposed acquisition involves equity participation in Vireo likely via the issuance of subordinate voting shares, and is expected to close in 1Q26.

THOUGHTS ON ACCRETION/VALUATION

While we suspect senior management will provide some color on deal-related accretion on the company's fourth quarter and full-year 2025 financial results conference call, our back-of-the-envelope math suggests a material step up in earnings power following the closing of the Schwazze, PharmaCann, and Eaze transactions. Beyond the rise in revenue related to VREOF's most recent transactions (partially offset by incremental corporate overhead, interest, and minority interest expenses), key organic growth drivers include the launch of adult-use sales in Minnesota, and a step up in New York revenues reflecting the commencement of adult-use sales from the company's indoor facility.

From a margin perspective, the integrations of Proper, Deep Roots, and Wholesome have largely been completed (including consolidating accounting, finance, human resources, insurance, and procurement operations), with related synergies likely to be fully realized this year. Furthermore, a favorable sales mix shift in favor of higher-margin recreational-use products in the retail channel, as well as management's continued focus on driving operational efficiencies and economies of scale more broadly likely result in a step up in profitability.

Turning to Adjusted EBITDA (excludes non-cash inventory adjustments and stock-based compensation expenses, as well as non-recurring items), our analysis points to material accretion related to the pending Schwazze, PharmaCann, and Eaze acquisitions.

From a valuation perspective, while we will wait until 4Q25 earnings to officially update our earnings model and \$1.50 DCF-derived price target, we look for a material upward revaluation for the stock, as deal-related accretion increasingly comes into focus. Indeed, the stock has traded down since the company reported 3Q25 earnings in mid-November despite the subsequent announcements of the PharmaCann and Eaze acquisitions, as well as the incremental investment in Schwazze. Moreover, Vireo remains uniquely positioned to continue to roll-up accretive assets, with further acquisitions likely representing incremental catalysts for the stock. Finally, a more favorable regulatory backdrop (particularly as it relates to federal rescheduling or incremental state legalizations) potentially drives potent business, economic, valuation, and/or uplisting benefits over time.

UPDATE ON RESCHEDULING

As widely covered, President Trump issued an executive order in mid-December 2025 instructing the attorney general to expedite the process of rescheduling marijuana to Schedule III of the Controlled Substances Act. Looking ahead, assuming the Drug Enforcement Administration (DEA) publishes a final rule in the Federal Register following Health and Human Services (HHS) scientific and medical evaluations, a public comment period, and potential hearings, we would expect opponent groups to immediately file a "petition for review" and request a "motion to stay" to suspend the effective date. If a judge denies the motion to stay, rescheduling takes effect. That said, if the stay is granted, the ruling remains suspended pending the outcome of related litigation, which could persist for multiple years.

Stepping back, the rescheduling of marijuana from Schedule I to Schedule III potentially paves the way for several key benefits for cannabis-related businesses. First, Internal Revenue Code Section 280E would no longer apply, thereby providing for the deduction of business expenses on federal tax returns. Beyond immediate cash flow benefits on a go-forward basis, cannabis companies likely settle outstanding liabilities with the government (VREOF carried \$85 million of uncertain tax liabilities on the balance sheet as of 9/30/25). Second, marijuana rescheduling likely improves access to banking/financial services for cannabis companies, thereby lowering costs of capital, all else equal. Third, less onerous tax burdens potentially promote stepped-up spending on marketing and/or research and development, thus enhancing sustainable growth across cycles. More broadly, lower regulatory/financial

barriers likely spur growth across the industry, with scale-enabled MSOs seemingly well positioned to gain market share, we believe.

As uncertainty around rescheduling probabilities, implications, and timelines fade, we look for cannabis stocks to benefit from powerful upward revaluations. Further catalysts include potential uplistings to senior exchanges (NYSE, Nasdaq) here in the U.S., which would undoubtedly enhance liquidity and institutional shareholder ownership for public-traded cannabis companies.

INVESTMENT THESIS

Vireo Growth is a vertically-integrated cannabis Multiple State Operator (MSO) involved in the cultivation, production, and distribution of a diversified suite of medical and recreational products across proprietary retail outlets and third-party dispensaries in wholesale markets.

Our investment thesis revolves around:

- 1. Transformational acquisitions:** Following the recently closed acquisitions of Wholesome (Utah), Proper Brands (Missouri), and Deep Roots Harvest (Nevada), the company's diversified operating footprint spans six states (including legacy markets in Maryland, Minnesota, and New York), eight cultivation facilities, and 38 dispensaries. The additions further strengthen Vireo's existing portfolio of high-quality products across distribution channels. Stepping back, management remains focused on building a diversified network of local operators across financially attractive and complementary markets. While independent management teams retain control of day-to-day operations, affiliated companies can leverage shared corporate services to facilitate operating efficiencies and enhance growth.
- 2. Multi-layered growth story:** Despite ongoing regulatory uncertainty, we see a number of broader industry and company-specific catalysts that position VREOF for accelerating growth going forward. First, U.S. cannabis industry revenues reached ~\$32 billion last year, with ongoing growth projected driven by further legalization at the state level, rising consumer demand, and a step up in the number of users reflecting growing adoption of cannabis to treat a wider array of medical conditions, as well as building acceptance/support for legalization efforts. Concentrating on Vireo, we suspect much of the standalone business's growth will come from Minnesota and New York, where management remains focused on building out cultivation/production capacity to meet building adult-use demand. Furthermore, following the previously announced transformational acquisitions, we believe Vireo has reached critical mass, with market shares continuing to roll up to scale-enabled MSOs.
- 3. Profitability inflection:** Our model calls for EPS to hit \$0.03 in 2026 reflecting full-year accretion from recent acquisitions, with further growth expected in 2027 and beyond as the business continues to scale. Focusing on the top line, we look for strong growth in 2026 and beyond following the closings of the Wholesome, Proper, and Deep Roots acquisitions, as well as the commencement of adult-use sales in Minnesota. Furthermore, we forecast a step up in New York revenue reflecting the recent initiation of adult-use sales from the company's indoor facility. Turning to margins, key expansion drivers likely include meaningful transaction-related accretion, as senior officials rationalize redundant corporate services across accounting/finance, legal, human resources, and other departments, a constructive mix shift in favor of more profitable sales of recreational-use products in the retail channel, and an ongoing focus on expense management.
- 4. Balance sheet remains a key differentiating factor:** Vireo's strong balance sheet remains a key competitive advantage relative to most other U.S.-based cannabis operators that typically struggle to source capital to fund growth due to regulatory restrictions, with highly-dilutive financings often the only course of action. Put another way, Vireo maintains ample liquidity to weather the storm and capitalize on accelerating consolidation trends across the industry should the regulatory backdrop remain challenging. Importantly, Vireo's debt profile remains generally favorable, with long-dated maturities (early 2027), not to mention sizeable credit facilities.

INVESTMENT RISKS

- 1. Regulatory uncertainty:** The cannabis regulatory landscape remains challenging characterized by ongoing bans at the federal level, a patchwork of differing rules and regulations across states, and continual competition from the black market. The federal Controlled Substances Act (CSA) criminalizes the manufacture, sale, and distribution of Schedule I drugs including marijuana, while the Bank Secrecy Act (BSA) requires depository and other financial institutions to ensure clients refrain from engaging in unlawful behavior, including the sales of marijuana, as well as maintain Anti-Money Laundering (AML) programs. As such, cannabis operators often struggle to access traditional financial services and funding from banking institutions, thereby driving elevated operating expenses and higher costs of capital, all else equal.
- 2. M&A integration/financing:** All transactions carry meaningful execution and operational risks. And while VREOF manages a decentralized platform leveraging independent operators' local expertise, business dislocation risk rises as accounting/finance, human resources, legal, and other back-office functions are consolidated. Looking ahead, management remains patient, but aggressive as it relates to potentially capitalizing on incremental M&A opportunities. That said, shareholders likely risk dilution, assuming prospective deals are at least partially financed with equity.
- 3. Rising competition:** The cannabis industry remains highly fragmented, with ~15,000 dispensaries across the U.S. managed by scale-enabled MSOs and smaller local operators (not to mention the unregulated black market). As such, competition remains fierce, with market shares rolling up to companies that can increasingly leverage superior cultivation and manufacturing capabilities, diversified/innovative product sets, broader retail distribution, more cost-effective marketing initiatives, wider access to financing, and improving operational efficiencies. One of the byproducts of rising competition has been ongoing pricing pressure. Lower prices combined with rising labor/materials costs linked to inflation continues to pressure industry margins, all else equal, with mounting cannabis exports and new market entrants potentially exacerbating the softening pricing trend.
- 4. Uncertain tax liabilities:** Section Rule 280E of the Internal Revenue Code prohibits companies that traffic in Schedule I or Schedule II controlled substances from deducting ordinary business expenses (with the exception of certain cultivation and manufacturing costs) resulting in outsized tax burdens and less capital to fund growth. Vireo filed amended tax returns for 2020, 2021, and 2022 that allow for standard business expense deductions. While it remains to be seen if the IRS challenges the deductions, one potential outcome is the company is forced to pay back taxes (plus interest).

PROJECTED INCOME STATEMENT

Vireo Growth Inc.
(\$ thousands)

	Quarterly								Annual				Y/Y Growth		
	1Q24	2Q24	3Q24	4Q24	1Q25	2Q25	3Q25	4Q25E	2023	2024	2025E	2026E	2024	2025E	2026E
	Mar-24	Jun-24	Sep-24	Dec-24	Mar-25	Jun-25	Sep-25	Dec-25	Dec-23	Dec-24	Dec-25	Dec-26	Dec-24	Dec-25	Dec-26
Revenue	24,087	25,108	25,165	25,023	24,541	48,063	91,655	94,205	88,133	99,384	258,464	440,794	13%	160%	71%
Cost of Sales:															
Product costs	12,147	11,517	12,448	12,207	11,695	23,719	40,878	42,015	42,740	48,319	118,308	194,830	13%	145%	65%
Non-cash product costs						4,152	12,398	0			16,550	0	NM	NM	-100%
Inventory valuation adjustments	(304)	41	393	164	433	(226)	996	0	1,289	294	1,203	0	-77%	309%	-100%
Gross profit	12,244	13,551	12,324	12,652	12,412	20,418	37,383	52,190	44,104	50,771	122,403	245,964	15%	141%	101%
Operating Expenses:															
Selling, general and administrative	7,052	7,564	6,911	6,812	7,474	12,455	29,681	30,036	28,218	28,063	79,645	136,131	-1%	184%	71%
Transaction related	0	0	0	4,227	1,245	4,729	804	0	0	4,504	6,778	0	NM	50%	-100%
Stock-based compensation	180	(61)	1,305	2,204	1,461	4,151	4,007	4,007	4,158	3,628	13,625	16,027	-13%	276%	18%
Depreciation	74	73	76	70	77	388	553	553	470	293	1,570	2,210	-38%	436%	41%
Amortization	180	180	180	180	180	714	1,530	1,530	679	720	3,955	6,121	6%	449%	55%
Total Operating Expenses	7,485	7,757	8,473	13,494	10,437	22,437	36,574	36,125	33,524	37,208	105,572	160,489	11%	184%	52%
Operating Income/(Loss)	4,759	5,794	3,851	(842)	1,976	(2,019)	809	16,065	10,580	13,563	16,831	85,475	28%	24%	408%
Other Income/(Expense):															
Interest expenses, net	(8,723)	(7,518)	(7,364)	(7,584)	(7,600)	(7,648)	(6,906)	(6,906)	(31,261)	(31,189)	(29,060)	(27,625)	NM	NM	NM
Impairment of long-lived assets	0	0	0	0	0	0	0	0	(412)	0	0	0	NM	NM	NM
Gain/(loss) on disposal of assets	(121)	(97)	0	0	0	(6)	(7,838)	0	(4,478)	(218)	(7,844)	0	NM	NM	NM
Other income/(expenses)	1,318	1,593	971	(2,933)	790	(408)	983	0	7,746	949	1,365	0	-88%	44%	-100%
Other income/(expenses), net	(7,526)	(6,022)	(6,393)	(10,517)	(6,809)	(8,061)	(13,761)	(6,906)	(28,404)	(30,458)	(35,538)	(27,625)	NM	NM	NM
Pre-Tax Income/(Loss)	(2,766)	(228)	(2,541)	(11,358)	(4,834)	(10,080)	(12,952)	9,159	(17,824)	(16,895)	(18,707)	57,850	NM	NM	NM
Current income tax expenses	(3,945)	(440)	(2,385)	(4,343)	(1,675)	(4,854)	(13,347)	(3,114)	(6,036)	(11,113)	(22,990)	(19,669)	NM	NM	NM
Deferred income tax recoveries	0	0	0	0	0	0	0	0	(1,687)	0	0	0	NM	NM	NM
Net Income/(Loss)	(6,711)	(668)	(4,926)	(15,701)	(6,509)	(14,934)	(26,299)	6,045	(25,547)	(28,008)	(41,697)	38,181	NM	NM	NM
Earnings/(loss) per share	(\$0.05)	(\$0.00)	(\$0.02)	(\$0.07)	(\$0.02)	(\$0.03)	(\$0.04)	\$0.01	(\$0.19)	(\$0.16)	(\$0.06)	\$0.03	NM	NM	NM
Weighted avg shares out (basic & diluted)	143,126	143,583	201,377	232,646	366,800	559,097	627,654	1,119,655	135,236	180,392	668,302	1,177,055	33%	270%	76%
Net income (loss)	(6,711)	(668)	(4,926)	(15,701)	(6,509)	(14,934)	(26,299)	6,045	(25,547)	(28,008)	(41,697)	38,181	NM	NM	NM
Interest expense, net	(8,723)	(7,518)	(7,364)	(7,584)	(7,600)	(7,648)	(6,906)	(6,906)	(31,261)	(31,189)	(29,060)	(27,625)	NM	NM	NM
Income taxes	(3,945)	(440)	(2,385)	(4,343)	(1,675)	(4,854)	(13,347)	(3,114)	(7,723)	(11,113)	(22,990)	(19,669)	NM	NM	NM
Depreciation & Amortization	(254)	(253)	(256)	(250)	(257)	(1,102)	(2,083)	(2,083)	(1,149)	(1,013)	(5,525)	(8,331)	NM	NM	NM
Depreciation & Amortization in COGS	(585)	(586)	(582)	(590)	(570)	(859)	(1,813)	(1,813)	(2,454)	(2,343)	(5,056)	(7,624)	NM	NM	NM
EBITDA	6,795	8,129	5,661	(2,934)	3,593	(472)	(2,149)	19,961	17,039	17,650	20,933	101,430	4%	19%	385%
Inventory adjustment	304	41	393	164	433	3,926	996	0	1,289	294	5,355	0	-77%	1722%	-100%
Non-cash inventory adjustment							12,398	0		0	12,398	0	NM	NM	-100%
Grown Rogue termination fee included in COGS					267	267	0	0	0	0	533	0	NM	NM	-100%
Loss on impairment of long-lived assets	0	0	0	0	0	0	0	0	412	0	0	0	-100%	NM	NM
Stock-based compensation	180	(61)	1,305	2,204	1,461	4,151	4,007	4,007	4,158	3,628	13,625	16,027	-13%	276%	18%
Transaction related expenses	0	0	0	4,227	1,245	4,729	804	0	0	4,504	6,778	0	NM	50%	-100%
Other income	(1,328)	(1,593)	(971)	2,933	(790)	408	(479)	0	(7,793)	(1,149)	(862)	0	NM	NM	NM
Debt financing costs							1,874	1,874	0	3,747	7,494	0	NM	NM	100%
Severance expense					380	240	74	0	0	694	0	0	NM	NM	-100%
Loss on disposal of assets	121	97	0	0	0	6	7,838	0	4,478	218	7,844	0	-95%	3493%	-100%
Adjusted EBITDA	6,071	6,613	6,388	6,594	6,588	13,254	25,362	25,841	19,583	25,145	71,045	124,951	28%	183%	76%

Source: Company reports and Zacks SCR estimates and calculations.


PROJECTED BALANCE SHEET

Vireo Growth Inc.
(\$ thousands)

	Quarterly								Annual				Y/Y Growth		
	<u>1Q24</u>	<u>2Q24</u>	<u>3Q24</u>	<u>4Q24</u>	<u>1Q25</u>	<u>2Q25</u>	<u>3Q25</u>	<u>4Q25E</u>	<u>2023</u>	<u>2024</u>	<u>2025E</u>	<u>2026E</u>	<u>2024</u>	<u>2025E</u>	<u>2026E</u>
	Mar-24	Jun-24	Sep-24	Dec-24	Mar-25	Jun-25	Sep-25	Dec-25	Dec-23	Dec-24	Dec-25	Dec-26	Dec-24	Dec-25	Dec-26
Assets															
Current assets:															
Cash	12,604	11,229	7,280	91,605	86,261	99,135	97,152	98,123	15,965	91,605	98,123	102,048	474%	7%	4%
Restricted Cash						7,055	20,388	20,592			20,592	21,415	NM	NM	4%
Marketable Securities						1,004	1,013	1,033			1,033	1,115	NM	NM	8%
Accounts receivable, net of credit losses	2,754	2,260	2,849	4,590	3,983	10,620	12,180	12,302	3,087	4,590	12,302	12,794	49%	168%	4%
Income tax receivable	12,103	12,262	11,917	12,027	11,367	24,760	14,414	14,559	12,278	12,027	14,559	15,141	-2%	21%	4%
Inventory	19,357	20,092	19,846	21,666	23,343	63,033	53,902	54,980	19,286	21,666	54,980	59,378	12%	154%	8%
Prepayments and other current assets	1,046	771	1,833	1,651	1,786	4,130	5,115	5,166	1,336	1,651	5,166	5,373	24%	213%	4%
Notes receivable, current	3,750	3,750	0	0	0	0	0	0	3,750	0	0	0	-100%	NM	NM
Warrants held	3,265	4,868	5,222	2,271	1,752	1,272	1,333	1,346	1,937	2,271	1,346	1,400	17%	-41%	4%
Assets Held for Sale	92,297	93,402	95,018	96,560	99,942	101,779	102,468	103,493	91,213	96,560	103,493	107,633	6%	7%	4%
Total current assets	147,177	148,635	143,964	230,371	228,434	312,788	307,965	311,593	148,852	230,371	311,593	326,298	55%	35%	5%
Property and equipment, net	23,541	26,262	30,509	32,312	32,836	110,660	121,242	122,454	23,291	32,312	122,454	127,353	39%	279%	4%
Operating lease, right-of-use asset	11,119	10,942	10,758	7,859	7,661	37,468	37,113	36,370	2,018	7,859	36,370	33,461	289%	363%	-8%
Notes receivable, long-term	0	0	0	0	0	0	0	0	0	0	0	0	NM	NM	NM
Intangible assets, net	8,514	8,309	8,104	7,899	7,695	86,174	89,652	87,859	8,719	7,899	87,859	80,830	-9%	1012%	-8%
Goodwill	0	0	0	0	0	72,644	97,289	97,289	0	0	97,289	97,289	NM	NM	0%
Investments						13,100	6,000	6,120			6,120	6,610	NM	NM	8%
Deposits	534	534	534	421	421	8,648	2,129	2,129	384	421	2,129	2,129	10%	406%	0%
Indemnified Assets						17,529	17,529	17,529			17,529	17,529	NM	NM	0%
Other assets						328	0	0			0	0	NM	NM	NM
Deferred tax assets	0	0	0	0	0	0	0	0	0	0	0	0	NM	NM	NM
Total Assets	190,884	194,681	193,869	278,863	277,047	659,340	678,919	681,344	183,264	278,863	681,344	691,498	52%	144%	1%
Liabilities															
Current liabilities:															
Accounts payable & accrued liabilities	7,970	9,176	9,169	10,456	12,197	47,455	38,543	38,929	7,674	10,456	38,929	40,486	36%	272%	4%
Convertible debt, current portion							1,650	1,650			1,650	1,650			
Long-Term debt, current portion	60,896	61,502	1,144	900	0	26,483	15,630	15,630	60,221	900	15,630	15,630	-99%	1637%	0%
Right of use liability	882	953	1,255	1,400	1,149	4,351	4,771	4,819	890	1,400	4,819	5,012	57%	244%	4%
Uncertain tax liability	26,116	26,726	28,766	33,324	34,959	75,849	84,818	85,666	22,356	33,324	85,666	89,093	49%	157%	4%
Derivative liability							161	162			162	169			
Liabilities held for sale	88,373	88,415	88,437	89,387	89,351	89,379	89,335	90,228	88,326	89,387	90,228	93,837	1%	1%	4%
Total current liabilities	184,238	186,773	128,770	135,467	137,657	243,518	234,909	237,085	179,467	135,467	237,085	245,877	-25%	75%	4%
Right-of-use liability	19,635	19,467	19,052	16,494	16,437	43,195	41,773	40,937	10,544	16,494	40,937	37,662	56%	148%	-8%
Other long-term liabilities	176	197	217	37	37	1,317	1,101	1,101	156	37	1,101	1,101	-76%	2854%	0%
Contingent consideration						10,631	14,919	14,919			14,919	14,919	NM	NM	0%
Convertible debt, net	9,410	9,682	0	9,862	9,875	9,887	8,246	8,256	9,140	9,862	8,256	8,298	8%	-16%	0%
Long-Term debt, net	0	1,121	56,833	61,438	62,604	82,214	131,665	131,665	0	61,438	131,665	131,665	NM	114%	0%
Total Liabilities	213,460	217,240	204,872	223,299	226,609	390,762	432,613	433,964	199,307	223,299	433,964	439,523	12%	94%	1%
Total Shareholders' Equity	(22,575)	(22,559)	(11,003)	55,564	50,438	268,578	246,306	247,380	(16,044)	55,564	247,380	251,975	NM	345%	2%
Total Liabilities & Shareholders' Equity	190,884	194,681	193,869	278,863	277,047	659,340	678,919	681,344	183,264	278,863	681,344	691,498	52%	144%	1%

Source: Company reports and Zacks SCR estimates and calculations.

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Michael Kim, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.

Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.

SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.